news & events

Check out what we’ve been up to and where can we connect!


Baricitinib + remdesivir superior to remdesivir alone for hospitalized adults with COVID-19: ACTT-2 results published in NEJM

April 24, 2021
Results of the Adaptive COVID-19 Treatment Trial (ACTT)-2 investigating combination treatment with baricitinib, a Janus kinase inhibitor, and remdesivir for the treatment of COVID-19 in hospitalized adults were published in the New England Journal of Medicine (NEJM) on March 4, 2021, showing that the combination treatment was superior to remdesivir alone.

Read more »


2022 WAC-CREP conference

March 17-19, 2022
At the 5th annual WAC-CREP conference, FHI Clinical employees are presenting findings from research being conducted within the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network.

Read more »

SCOPE: Summit for Clinical Ops Executives

February 7-10, 2022
Attending SCOPE? Learn more about how we ensure best-fit sites with the most appropriate capabilities and patient populations tailored to your study protocol. Contact us to set aside time to review your feasibility and study start-up needs.

Read more »